STAT+: Biotech raises $42 million to run Huntington’s disease trial
Gene therapy startup Latus Bio has raised $42 million to fund its first clinical trials, including one for Huntington's disease. The company is also advancing a treatment for CLN2 disease, a rare genetic disorder, with initial clinical data expected by year-end. Latus Bio was founded by Beverly Davidson, chief scientific strategy officer at the Children’s Hospital of Philadelphia.
- ▪Latus Bio raised $42 million to support clinical trials for gene therapies.
- ▪The company is developing treatments for Huntington’s disease and CLN2 disease, a fatal form of Batten disease.
- ▪Latus Bio anticipates releasing initial clinical data for its CLN2 therapy by the end of the year.
- ▪The company plans to seek FDA permission to begin its Huntington’s disease trial in the coming months.
- ▪Latus Bio was founded by Beverly Davidson of the Children’s Hospital of Philadelphia.
Opening excerpt (first ~120 words) tap to expand
STAT PlusExclusive Biotech raises $42 million to run Huntington’s disease trial Latus Bio plans to seek FDA permission to start the clinical trial in the next few months Manage alerts for this article Email this article Share this article ZEPHYR / SCIENCE PHOTO LIBRARY By Allison DeAngelisMay 4, 2026 Biotech Startups and Venture Capital Reporter Allison DeAngelis[email protected]Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at STAT.
Discussion
0 commentsMore from STAT
